EcoDrugPlus

Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1-Like

Ensembl ID : ENSPNYG00000016895
Gene Symbol: LOC102194418
2 Cross references
195 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSPNYG00000017969
Gene Symbol: LOC102208075
3 Cross references
195 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSPNYG00000002076
Gene Symbol: LOC102209405
2 Cross references
185 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSPNYG00000002358
Gene Symbol: LOC102199093
3 Cross references
189 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSPNYG00000010590
Gene Symbol: NPR1
3 Cross references
190 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSPNYG00000006297
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSPNYG00000004505
Gene Symbol: LOC102204142
3 Cross references
196 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSPNYG00000014320
Gene Symbol: LOC102201575
3 Cross references
197 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSPNYG00000008965
Gene Symbol: LOC102208216
3 Cross references
218 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSPNYG00000013286
Gene Symbol: LOC102199165
3 Cross references
193 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSPNYG00000013731
Gene Symbol: NPY2R
3 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Y4

Ensembl ID : ENSPNYG00000020969
Gene Symbol: NPY4R
1 Cross references
135 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).